Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hong Kong regulators may be beefing up GMPs

This article was originally published in The Gold Sheet

Executive Summary

A review of Hong Kong's drug regulatory infrastructure could lead to more stringent GMP requirements for pharmaceutical manufactures, importers and distributors. A number of recent incidents have shaken public confidence in Hong Kong's regulatory system. The incidents ranged from drugs with fabricated expiration dates to tainted products distributed through government-run hospitals that have been linked to the deaths of six cancer patients. Under current regulations, manufacturers are responsible for registering locally made products. For imported products, the registration burden falls on the importer. Generic drugs that have been registered for more than five years do not have to produce clinical or scientific documentation on efficacy. Hong Kong regulators have enlisted the help of Australian drug experts to guide them in setting manufacturing standards for pharmaceuticals

You may also be interested in...



Centus Gets European Bevacizumab Approval

Centus Biotherapeutics has received formal European Commission approval for its Equidacent biosimilar rival to Avastin.

IGBA Calls For ‘Streamlining’ Of Global Biosimilars Process

The IGBA has called for a “streamlined” global biosimilar development and registration process, with a new policy paper highlighting the limited value of comparative efficacy clinical data at the same time as it urges renewed efforts on educating healthcare professionals.

Regeneron’s COVID-19 Antibody Cocktail Shows Early Promise, But Does It Merit An EUA?

Data from the first 275 patients in the trial are promising, but outside experts say they are wary of another hasty Emergency Use Authorization.

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel